Casirivimab-imdevimab treatment is associated with reduced rates of mortality and hospitalization in patients with COVID-19: A systematic review with meta-analysis - 06/06/23
Doi : 10.1016/j.jinf.2023.04.019
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | Included studies reported the impact of casirivimab-imdevimab on clinical outcomes. |
• | A total of 9 articles comprising 407,818 adult patients with COVID-19 were included in the analysis. |
• | Pooled outcomes indicated casirivimab-imdevimab was associated with a lower risk of mortality and hospitalization. |
Plan
© 2023
The British Infection Association. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 87 - N° 1
P. 82-84 - juillet 2023 Retour au numéro
Article précédent
- Undetectable intrauterine transmission during the first trimester of pregnancy in woman after COVID-19 infection
- Jian Xu, Di Mao, Peiling Liang, Peng Du, Xiaomeng Zhang, Xiaoyan Dang, Haiying Wu, Bing Zhu, Ling Sun
- Impact of COVID-19 control measures on Legionella pneumophila infections in children in Henan, China
- Yang Zhou, Hui Yan, Qiang Zhou, Ruiling Feng, Bo Zhai
Bienvenue sur EM-consulte, la référence des professionnels de santé.